文献速递药物不良反应与药物警戒

基层医疗数据库评估EU药物警戒风险评估委员会讨论药物的能力

Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee.
PubMed 文献 · Clin Pharmacol Ther · 2020-02-12

评估83个集中授权和45个国家授权产品显示,上市时间越长覆盖越好,孤儿药覆盖较差。检测与假设对照的关联能力对更常见事件和更大效应量更好。

要点

  • 上市时间较长的产品在基层医疗数据库中覆盖更好,孤儿药覆盖较差。
  • 检测药物-事件关联的能力在更常见事件和更大效应量时更优。
  • 高级治疗药物若在专科而非基层使用,数据库覆盖较差。

核心结论

  • 基层医疗数据库对孤儿药及专科使用的高级治疗药物覆盖有限。
  • 为支持更好监管决策,需获取补充数据源,尤其涵盖二级医疗处方。

研究设计与样本

  • 数据库包括IQVIA英国、法国、德国及CPRD Aurum,覆盖至2018年8月31日。
  • 评估83个集中授权产品和45个国家授权产品。

主要发现

  • 产品覆盖对上市时间较长者更好,孤儿药较差。
  • 检测与假设对照关联的能力对更常见事件和更大效应量更好。
  • 高级治疗药物在专科而非基层给药时覆盖更差。

临床怎么用

  • 利用基层医疗数据库评估药物暴露时需考虑孤儿药和专科药物的覆盖局限。
  • 监管决策应整合补充数据源,尤其二级医疗处方数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study measured the exposure to different categories of medicinal products discussed by the European Union (EU) Pharmacovigilance Risk Assessment Committee from September to November 2018 in four electronic primary care health databases: IQVIA Medical Research Data-UK, IQVIA Medical Research Data-France, IQVIA Medical Research Data-Germany, and Clinical Practice Research Datalink Aurum, in the entire lifespan of each database until August 31, 2018. The assessment of 83 centrally authorized products and 45 nationally authorized products showed that coverage was better for products marketed for longer duration and worse for orphan drugs. The ability to detect associations against hypothetical comparators was better for more common events and for larger effect sizes. Coverage of advanced therapies was worse for those typically administered in a specialized rather than primary care setting. This study shows that to enable better informed regulatory decisions there is a need to access complementary data sources, particularly capturing secondary care prescribing.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Flynn R, Hedenmalm K, Murray-Thomas T, et al. Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. Clin Pharmacol Ther. 2020. PMID: 31955404. doi:10.1002/cpt.1775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。